The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
Early studies indicated the development of DAD, the 'chemotherapy lung' or the hemolytic and uremic syndrome in patients receiving FU in association with mitomycin C.
More recent cases described the complication in patients who received FOLFOX or FOLFIRI regimens. Corticosteroids were efficacious in a few cases
Publications
Pulmonary toxicity with oxaliplatin and capecitabine/5-Fluorouracil chemotherapy: a case report and review of the literature.
Onkologie 2011;34;443-6 — 2011 — 443-6
Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancellieri A, Patelli M, Falcone F, Poletti V
Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.
The European respiratory journal 2001 Jul;18;243-5 — 2001 Jul — 243-5